Lacosamide (Vimpat ®)

Assessment Status Rapid Review Complete
Drug Lacosamide
Brand Vimpat®
Indication As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).
Assessment Process
Rapid review commissioned 11/09/2017
Rapid review completed 31/10/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended at the submitted price